Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration GlobeNewswire - Wed May 27, 7:47AM CDT

Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual...

AIM : 0.4078 (-6.47%)
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement GlobeNewswire - Wed May 20, 2:02PM CDT

OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM)  (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered...

AIM : 0.4078 (-6.47%)
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities GlobeNewswire - Tue May 19, 7:02AM CDT

OCALA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced a significant increase in stockholder equity and that the...

AIM : 0.4078 (-6.47%)
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer GlobeNewswire - Thu May 14, 7:41AM CDT

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary...

AIM : 0.4078 (-6.47%)
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds GlobeNewswire - Fri May 8, 7:40AM CDT

OCALA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech, Inc. (NYSEAM:AIM) (“AIM ImmunoTech” or the “Company”), a late-stage biotechnology company focused on the discovery and development...

AIM : 0.4078 (-6.47%)
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential GlobeNewswire - Thu May 7, 7:23AM CDT

OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced the Final Primary Endpoint Report on Objective Response...

AIM : 0.4078 (-6.47%)
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP GlobeNewswire - Thu Apr 16, 8:00AM CDT

Company to participate in Live Virtual Investor Closing Bell segment today, April 16 th  at 4:00 PM ET ; Register for the event  here OCALA, Fla., April 16, 2026 (GLOBE NEWSWIRE) --...

AIM : 0.4078 (-6.47%)
AIM ImmunoTech Provides Routine Update on Annual Filings GlobeNewswire - Mon Apr 13, 5:00PM CDT

OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the...

AIM : 0.4078 (-6.47%)
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event GlobeNewswire - Thu Apr 9, 7:00AM CDT

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16 th  at 4:00 PM ET   Register for the event here OCALA, Fla., April 09, 2026 (GLOBE...

AIM : 0.4078 (-6.47%)
accesso® Acquires Dexibit®, Establishing the First Cross Platform AI and Analytics Platform for Visitor Attractions PR Newswire - Mon Mar 30, 1:01AM CDT

Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation

AIM : 0.4078 (-6.47%)

Barchart Exclusives

Barclays Says Sandisk’s New AI Contracts Could Change the Memory Industry Barchart - Sun May 31, 2:00PM CDT
Sandisk stock is surging after Barclays highlighted the company’s aggressive long-term AI memory contracts and structurally stronger earnings outlook. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.